To determine the potentiating effect of knockdown of PLCG2 on anti-PD-1 therapy, we compared the tumor inhibition rate of this therapy in the control group (shnc-PLCG2) with that in the knockdown group (sh-PLCG2). This evidence concerns the gene PLCG2 and neoplasm.